SCHEMBL8316604

SCHEMBL8316604

COc1cccc2c1OC(CNCc1cccc3ccccc13)CC2

nearest known ligand 0.58

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
NFKB1 P19838 7/20 0.55
NFKB2 Q00653 7/20 0.55
RELA Q04206 7/20 0.55
HTR1A P08908 1/20 0.49
HTR1D P28221 1/20 0.49
HCRTR1 O43613 2/20 0.45
HCRTR2 O43614 2/20 0.45
SMPD1 P17405 1/20 0.43
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
DRD2 P14416 1/20 0.42
DRD4 P21917 1/20 0.42
DRD3 P35462 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL7319272 0.99 NFKB1 (0.54) NFKB1NFKB2RELAHTR1AHTR1D
SCHEMBL21092001 0.81 NFKB1 (0.54) NFKB1NFKB2RELAHTR1AHTR1D
SCHEMBL21091998 0.81 NFKB1 (0.54) NFKB1NFKB2RELAHTR1AHTR1D
SCHEMBL7319517 0.78 NFKB1 (0.52) NFKB1NFKB2RELAHCRTR1HCRTR2
SCHEMBL7395318 0.78 NFKB1 (0.52) NFKB1NFKB2RELAHTR1AHTR1D
SCHEMBL8317135 0.78 CYP2D6 (0.43) NFKB1NFKB2RELAHCRTR1HCRTR2
SCHEMBL7321215 0.77 HTR1A (0.56) NFKB1NFKB2RELAHTR1AHTR1D
SCHEMBL7317381 0.77 HTR1A (0.56) NFKB1NFKB2RELAHTR1AHTR1D
SCHEMBL7307892 0.77 HTR1A (0.56) NFKB1NFKB2RELAHTR1AHTR1D
SCHEMBL7318030 0.77 HTR1A (0.56) NFKB1NFKB2RELAHTR1AHTR1D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0540914-B1 2-Aminomethylchromans as active ingredients in medicaments for the treatment of diseases of the central nervous system BAYER AG (DE) 1999-06-02 EP disclosed
EP-0540914-A1 2-Aminomethylchromans as active ingredients in medicaments for the treatment of diseases of the central nervous system BAYER AG (DE) 1993-05-12 EP disclosed